154 related articles for article (PubMed ID: 21117615)
1. Superior preclinical efficacy of gemcitabine developed as chitosan nanoparticulate system.
Arias JL; Reddy LH; Couvreur P
Biomacromolecules; 2011 Jan; 12(1):97-104. PubMed ID: 21117615
[TBL] [Abstract][Full Text] [Related]
2. Polymeric nanoparticulate system augmented the anticancer therapeutic efficacy of gemcitabine.
Arias JL; Reddy LH; Couvreur P
J Drug Target; 2009 Sep; 17(8):586-98. PubMed ID: 19694612
[TBL] [Abstract][Full Text] [Related]
3. Site specific/targeted delivery of gemcitabine through anisamide anchored chitosan/poly ethylene glycol nanoparticles: an improved understanding of lung cancer therapeutic intervention.
Garg NK; Dwivedi P; Campbell C; Tyagi RK
Eur J Pharm Sci; 2012 Dec; 47(5):1006-14. PubMed ID: 23041219
[TBL] [Abstract][Full Text] [Related]
4. Long-circulatory nanoparticles for gemcitabine delivery: Development and investigation of pharmacokinetics and in-vivo anticancer efficacy.
Khare V; Singh A; Mahajan G; Alam N; Kour S; Gupta M; Kumar A; Singh G; Singh SK; Saxena AK; Mondhe DM; Gupta PN
Eur J Pharm Sci; 2016 Sep; 92():183-93. PubMed ID: 27404580
[TBL] [Abstract][Full Text] [Related]
5. A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types.
Reddy LH; Dubernet C; Mouelhi SL; Marque PE; Desmaele D; Couvreur P
J Control Release; 2007 Dec; 124(1-2):20-7. PubMed ID: 17878060
[TBL] [Abstract][Full Text] [Related]
6. Role of chitosan nanoparticles in the oral absorption of Gemcitabine.
Derakhshandeh K; Fathi S
Int J Pharm; 2012 Nov; 437(1-2):172-7. PubMed ID: 22909993
[TBL] [Abstract][Full Text] [Related]
7. Design and evaluation of an intravesical delivery system for superficial bladder cancer: preparation of gemcitabine HCl-loaded chitosan-thioglycolic acid nanoparticles and comparison of chitosan/poloxamer gels as carriers.
Şenyiğit ZA; Karavana SY; İlem-Özdemir D; Çalışkan Ç; Waldner C; Şen S; Bernkop-Schnürch A; Baloğlu E
Int J Nanomedicine; 2015; 10():6493-507. PubMed ID: 26508855
[TBL] [Abstract][Full Text] [Related]
8. Development and characterization of folic acid-conjugated chitosan nanoparticles for targeted and controlled delivery of gemcitabinein lung cancer therapeutics.
Wang F; Wang Y; Ma Q; Cao Y; Yu B
Artif Cells Nanomed Biotechnol; 2017 Dec; 45(8):1530-1538. PubMed ID: 27894196
[TBL] [Abstract][Full Text] [Related]
9. Chitosan-Pluronic nanoparticles as oral delivery of anticancer gemcitabine: preparation and in vitro study.
Hosseinzadeh H; Atyabi F; Dinarvand R; Ostad SN
Int J Nanomedicine; 2012; 7():1851-63. PubMed ID: 22605934
[TBL] [Abstract][Full Text] [Related]
10. Preparation and characterization of folate-chitosan-gemcitabine core-shell nanoparticles for potential tumor-targeted drug delivery.
Xu S; Xu Q; Zhou J; Wang J; Zhang N; Zhang L
J Nanosci Nanotechnol; 2013 Jan; 13(1):129-38. PubMed ID: 23646707
[TBL] [Abstract][Full Text] [Related]
11. Antitumoral activity of PEG-gemcitabine prodrugs targeted by folic acid.
Pasut G; Canal F; Dalla Via L; Arpicco S; Veronese FM; Schiavon O
J Control Release; 2008 May; 127(3):239-48. PubMed ID: 18346806
[TBL] [Abstract][Full Text] [Related]
12. Biocompatible gemcitabine-based nanomedicine engineered by Flow Focusing for efficient antitumor activity.
Martín-Banderas L; Sáez-Fernández E; Holgado MÁ; Durán-Lobato MM; Prados JC; Melguizo C; Arias JL
Int J Pharm; 2013 Feb; 443(1-2):103-9. PubMed ID: 23299085
[TBL] [Abstract][Full Text] [Related]
13. Loading of Gemcitabine on chitosan magnetic nanoparticles increases the anti-cancer efficacy of the drug.
Parsian M; Unsoy G; Mutlu P; Yalcin S; Tezcaner A; Gunduz U
Eur J Pharmacol; 2016 Aug; 784():121-8. PubMed ID: 27181067
[TBL] [Abstract][Full Text] [Related]
14. Molecular dynamics simulation study of chitosan and gemcitabine as a drug delivery system.
Razmimanesh F; Amjad-Iranagh S; Modarress H
J Mol Model; 2015 Jul; 21(7):165. PubMed ID: 26044358
[TBL] [Abstract][Full Text] [Related]
15. Thermosensitive polymer prodrug nanoparticles prepared by an all-aqueous nanoprecipitation process and application to combination therapy.
Guerassimoff L; Ferrere M; Van Herck S; Dehissi S; Nicolas V; De Geest BG; Nicolas J
J Control Release; 2024 May; 369():376-393. PubMed ID: 38554772
[TBL] [Abstract][Full Text] [Related]
16. Enhanced antiproliferative activity of Herceptin (HER2)-conjugated gemcitabine-loaded chitosan nanoparticle in pancreatic cancer therapy.
Arya G; Vandana M; Acharya S; Sahoo SK
Nanomedicine; 2011 Dec; 7(6):859-70. PubMed ID: 21550422
[TBL] [Abstract][Full Text] [Related]
17. Anticancer efficacy of squalenoyl gemcitabine nanomedicine on 60 human tumor cell panel and on experimental tumor.
Reddy LH; Renoir JM; Marsaud V; Lepetre-Mouelhi S; Desmaële D; Couvreur P
Mol Pharm; 2009; 6(5):1526-35. PubMed ID: 19634915
[TBL] [Abstract][Full Text] [Related]
18. Surface-modified gemcitabine with mucoadhesive polymer for oral delivery.
Lim JH; You SK; Baek JS; Hwang CJ; Na YG; Shin SC; Cho CW
J Microencapsul; 2012; 29(5):487-96. PubMed ID: 22783823
[TBL] [Abstract][Full Text] [Related]
19. N-trimethyl chitosan nanoparticles and CSKSSDYQC peptide: N-trimethyl chitosan conjugates enhance the oral bioavailability of gemcitabine to treat breast cancer.
Chen G; Svirskis D; Lu W; Ying M; Huang Y; Wen J
J Control Release; 2018 May; 277():142-153. PubMed ID: 29548985
[TBL] [Abstract][Full Text] [Related]
20. N-trimethyl chitosan coated nano-complexes enhance the oral bioavailability and chemotherapeutic effects of gemcitabine.
Chen G; Svirskis D; Lu W; Ying M; Li H; Liu M; Wen J
Carbohydr Polym; 2021 Dec; 273():118592. PubMed ID: 34560993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
